Phase 3 trials of the oral nonpeptide show glycemic and weight benefit when added to glargine and compared with dapagliflozin and oral semaglutide, but with somewhat lower tolerability.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/oral-glp-1-orforglipron-performs-well-phase-3-t2d-trials-2026a1000jfv?src=rss
Author :
Publish date : 2026-06-10 13:30:00
Copyright for syndicated content belongs to the linked Source.
